Donaperminogene seltoplasmid - VM BioPharma

Drug Profile

Donaperminogene seltoplasmid - VM BioPharma

Alternative Names: Donaperminogene seltoplasmid; Modified hepatocyte growth factor gene therapy; NL003; pCK-HGF-X7; VM-202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RY

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Beijing Northland Biotech; Reyon Pharmaceutical; ViroMed
  • Class Gene therapies; Growth factors; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer; Diabetic neuropathies
  • Phase II Peripheral arterial disorders
  • Phase I/II Amyotrophic lateral sclerosis
  • Phase I Ischaemic heart disorders; Myocardial ischaemia

Most Recent Events

  • 06 Dec 2017 Northwestern University plans a phase II trial for Peripheral Artery Disease in January 2018 (NCT03363165)
  • 13 Nov 2017 Phase-I development is ongoing in Ischaemic heart disorders in South Korea and Myocardial ischaemia in South Korea and USA and preclinical development in Myocardial ischaemia is ongoing in South Korea
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders in South Korea (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top